India's Zydus Cadila Seeks Nod For Its 3-Dose, "Needle-Free" Vaccine
NDTV
An approval for ZyCoV-D would make it the fifth vaccine cleared for use in India after Serum Institute of India's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V and the US-made Moderna.
Zydus Cadila has requested emergency use approval for its ZyCoV-D three-dose Covid shot that is the "world's first Plasmid DNA vaccine". The shot is "needle-free", says the company, and "safe for children". The company plans to manufacture up to 120 million doses of the shot annually. An approval for ZyCoV-D would make it the fifth vaccine cleared for use in India after Serum Institute of India's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V and the US-made Moderna. Zydus claims its vaccine is 66.6 per cent effective against symptomatic Covid cases and 100 per cent for moderate disease. It also says the vaccine is safe for children between 12 and 18 years.More Related News